Sexual Dysfunction Drugs – New Study Exploring Potentials of Established and Recently Approved Drugs, Industry Changes and Emerging Opportunities Are you interested in the future of treatments for sexual disorders? Our new analysis forecasts drug revenues for male and female treatments. There you explore sales results, R&D and opportunities, seeing changing trends and commercial prospects.
Discover, from 2015, progress, opportunities and revenues. Drugs our study covers include treatments for erectile dysfunction (ED), Peyronie’s disease and female hypoactive sexual desire disorder (HSDD). See the effect of recent drug approvals.
Please read on to explore that industry and see what future revenue it could generate.
Predictions and other analysis to benefit your research, plans and decisions Visiongain’s report gives revenue predictions to 2026 at overall world market, submarket, product and national level. Avoid falling behind in data or losing influence.
The future holds promise for pharma companies treating sexual dysfunction. New products enter that market and clinical testing shows commercial potential, especially for HSDD. Discover, from 2015, what revenues and other progress are possible.
Besides revenue forecasting to 2026, our new work shows recent results and market shares. There you find original analysis. You assess research and development too. Also gain 48 tables, 55 charts and two interviews with companies.
Forecasts covering the overall world market and segments for sexual disorder treatments Discover in our new analysis revenue predictions to 2026 for four drug classes at world level. See what is possible for these submarkets: • PDE5 inhibitors • Prostaglandins • Androgens • Gonadotrophins • Other drug classes (grouped).
Our work also divides the overall world market into revenues for male and female treatments.
With our survey you assess outlooks for revenue expansion, seeing where you can gain. You also investigate competitors’ actions, technologies and outlooks.
That way you see how those genitourinary medicines develop. You discover where needs and business opportunities exist. With a rising incidence of sexual disorders, the demand for better treatments will continue to enrich the pharmaceutical industry.
Our study also explores sales forecasts by product, showing how those agents can perform. See what gains are possible.
Predictions of leading products’ sales – what is possible for that industry’s top drugs? How will individual sexual disorder medicines perform from 2015 to 2026 at world level? Our study gives 14 product-level forecasts, including for these brands: • Cialis • Viagra • Gonal-F • Levitra • Nebido • Testim • Priligy • Tostran
The report also assesses emerging therapies: Vitaros, Addyi and Xiapex.
With that analysis you hear how high sales can go, finding products and years with highest predicted revenues. You also examine competition. Explore challenges, trends, competitors and opportunities.
Our work also shows you geographical predictions by leading country.
National markets – what outlooks for those sexual medicine revenues? Our work shows you individual revenue forecasts to 2026 for 11 national markets: • US • Japan • Germany, France, UK, Spain, Italy (EU5) • Brazil, Russia, India, China (BRIC) • Rest of world (grouped analysis).
Visiongain forecasts that BRIC countries will show the fastest growth and account for 17% of the overall world market by 2026. The rise of that region’s sales will be driven, in particular, by revenues in China and India.
The recent FDA approval of Addyi (flibanserin), for hypoactive sexual desire disorder, gives a breakthrough for female sexual dysfunction treatment. Suppliers of therapies will take encouragement from that development serving a large, emerging need.
Our report also shows trends leading to novel and improved treatments, forces changing that market.
Events and changes affecting companies treating sexual disorders Explore other issues, too, including influences and treatment needs shaping that industry and market: • Male sexual problems – erectile dysfunction, priapism, Peyronie’s disease, premature ejaculation, hypogonadism • Female sexual disorders – HSDD, difficulty achieving orgasm, persistent sexual arousal syndrome, sexual pain, dyspareunia, vaginismus, vulvodynia • Drug approvals for Peyronie’s disease and female sexual dysfunction • Developments in diagnosis, reporting of difficulties to doctors and willingness to treat those conditions • Research and development for male and female therapies, including advances in drug delivery.
Our study also gives SWOT and STEP analyses, exploring what drives and restrains that prominent, developing market.
See, then, what is possible for leading pharma companies and specialist firms.
Leading organisations and overall 2019 market value – what revenues are possible? Our work predicts the world market for those drugs will reach $7.7bn in 2019. That industry will achieve revenue expansion from 2015 to 2026. With our analysis you discover how high sales can go. Assess the gains possible.
For sexual disorder therapies you also explore the industry’s leading companies. They include Eli Lilly, Pfizer, Merck KGaA, Merck & Co., Ipsen and Bayer.
You also gain exclusive interviews with Palatin Technologies and Futura Medical. Discover what the future holds for companies in that market.
7 ways Male and Female Sexual Dysfunctions: Drug Market Report and Forecasts 2016-2026 helps you Our new investigation benefits your work in these seven main ways, helping you stay ahead in knowledge: • Revenues for sexual dysfunction drug therapies to 2026 – assess that overall world market’s potential, seeing scope for investments, developments, production and marketing • Submarket revenues to 2026 covering four therapeutic segments – explore treatment categories, seeing their sales outlooks from 2015 • Leading products’ sales to 2026 – discover predicted revenues of 14 top brands, assessing how those medicines can compete and succeed • Forecasting to 2026 for 11 countries in the Americas, Europe and Asia – explore the best regions for treatment demand, sales and revenue growth • R&D activities – see progress, trends and prospects in that research and development, finding technological, clinical and commercial possibilities • Companies, news and opinion – examine participants in that progressing market, gaining insight to help you stay ahead and benefit your influence • Analysis of what stimulates and restrains that market – assess challenges and strengths there, helping you compete and gain advantages.
That analysis, by our in-house team in the UK, benefits anyone exploring that market. It shows data you find nowhere else, helping you succeed.
Gain predictions for treating sexual dysfunction, staying ahead With our independent study you explore products, companies, progress and possibilities. Discover what the future holds for that market and its companies.
Having that information means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort, also benefiting your plans, decisions, presentations, proposals and authority.
Our investigation shows data, trends, opportunities and forecasts for that expanding pharma market. So avoid missing out – please get our new report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Overview of the World Market for Sexual Dysfunctions Treatment 1.2 Why You Should Read This Report 1.3 How This Study Delivers 1.4 Main Questions Answered by this Analysis 1.5 Who is this Report For? 1.6 Methods of Research and Analysis 1.7 Frequently Asked Questions (FAQs) 1.8 Some Associated Reports 1.9 About Visiongain
2. Introduction to Sexual Dysfunctions and Treatment Options 2.1 Diagnosis – ICD-10 and DSM-V 2.2 Male Sexual Dysfunctions 2.2.1 Sexual Desire Dysfunctions 2.2.2 Erectile Dysfunction 2.2.3 Priapism 2.2.4 Peyronie’s Disease 2.2.5 Premature Ejaculation 2.2.6 Hypogonadism 2.3 Female Sexual Dysfunctions 2.3.1 Dysfunctions of Arousal 2.3.2 Persistent Sexual Arousal Syndrome 2.3.3 Dysfunctions of Orgasm 2.3.4 Sexual Pain Dysfunctions 2.3.4.1 Dyspareunia 2.3.4.2 Vaginismus 2.3.5 Vulvodynia
3. The World Sexual Dysfunctions Drugs Market, 2015-2026 3.1 Global Sexual Dysfunctions Drugs Forecast 2015-2026 3.2 Sexual Dysfunction Drugs Market by Drug Class 3.2.1 PDE5 Inhibitors – Still Hold the Biggest Market Share 3.2.2 Prostaglandins – Dominated by Alprostadils 3.2.3 Androgens – Will New Delivery Technology Drive This Submarket? 3.2.4 Gonadotrophins – New Products Launched Expected 3.2.5 Other Drug Classes Market – Will See Significant Growth 3.3 Sexual Dysfunctions Drugs Market by Gender 3.3.1 Male Sexual Dysfunctions Drugs Market 2015-2026 – Declining as Originator Drugs Lose Patent Protection 3.3.2 Female Sexual Dysfunctions Drugs Market 2015-2026 – a Developing Market Holding Promising Commercial Potential
4. Sexual Dysfunction-Treating Drugs: Revenue Forecasts, 2015-2026 4.1 Cialis (Eli Lilly) – Faces Patent Expiry 4.2 Viagra (Pfizer) – Will Extended Patent in the US Protect Revenue? 4.3 Gonal-F (Merck KGaA) – Slow Growth in the First Half of the Forecast Period 4.4 Puregon (Merck & Co.) – Expected to Decline Significantly 4.5 Decapeptyl SR (Ipsen Ltd) – Growing Until the End of the First Half of the Forecast Period 4.6 Caverject Dual Chamber (Pfizer) – Growing During the First Half of the Forecast Period 4.7 Levitra (Bayer) – Sales Eroded by Cheaper PDE5 Inhibitors? 4.8 Nebido (Bayer) – Intramuscular Formulation of Testosterone Undecanoate 4.9 Testim (Ferring Pharmaceuticals) – Differentiated by Consistent Transdermal Absorption 4.10 Priligy (J&J/A. Menarini Pharma UK SRL) – SSRI to Treat Premature Ejaculation 4.11 Stendra/Spedra (VIVUS/Endo/Auxilium Pharmaceuticals) – Newest PDE5 Inhibitor 4.12 MUSE (Meda Pharmaceuticals) – Suppository Prostaglandin 4.13 Viridal Duo/Edex (UCB Pharma/Auxilium Pharmaceuticals) – Growing Strongly in the First Half of the Forecast Period 4.14 Tostran (ProStrakan Pharmaceuticals) – Eroded by Generic Competition Since 2014 4.15 Vitaros (Takeda) – Topical Formulation of Alprostadil 4.16 Restandol Testocaps (Merck & Co.) – Testosterone Replacement 4.17 Sustanon 250 (Aspen Pharma Trading) – Preferred Testosterone Replacement in the UK 4.18 Bemfola (Finox Biotech UK & Ireland Ltd.) – Biosimilar 4.19 Menopur (Ferring Pharmaceuticals) – a Preparation of Gonadotrophins 4.20 Pregnyl (Merck & Co.) – to Treat Hypogonadism 4.21 Androcur (Bayer Plc) – to Treat Androgen-related Conditions 4.22 Gonapeptyl (Ferring Pharmaceuticals) – Depot Injection 4.23 Intrinsa (Procter & Gamble) – Testosterone Patch
5. Emerging Therapies for Sexual Disorders 5.1 Vitaros (Takeda) – Topical Cream to Treat Erectile Dysfunction 5.2 Addyi (Sprout/Valeant Pharmaceuticals) – First Approved Drug for Female Sexual Dysfunction 5.3 Xiapex (Auxilium Pharmaceuticals)- First Approved Drug for Peyronie’s Disease
6. Leading Companies in the Sexual Dysfunction Drugs Market 6.1 Eli Lilly – Leading With Cialis 6.2 Pfizer – Will It Overtake Eli Lilly in This Forecast Period? 6.3 Merck KGaA – Driven by Sales in Emerging Markets 6.4 Merck & Co. – Will It Soon Lose Its Share to Competitors? 6.5 Ipsen Ltd – Ongoing Clinical Trials for Decapeptyl May Drive Further Growth 6.6 Bayer – Orodispersible Form of Levitra Not Pushing Revenue?
7. Leading National Markets: Revenue Forecasts, 2015-2026 7.1. The US Sexual Dysfunctions Drugs Market, 2015-2026 – Leader of the Pack 7.2. The Japanese Sexual Dysfunctions Drugs Market, 2015-2026 – Still Driven by Viagra and Cialis Sales 7.3 EU5 Sexual Dysfunctions Drugs Market, 2015-2026 – Cost Containment Will Slow the Market 7.4 BRIC Sexual Dysfunctions Drugs Market, 2015-2026 – Driven by Growth in China and India 7.5 Other Regions’ Sexual Dysfunctions Drugs Market, 2015-2026 – Expected High Growth Rate
8. R&D Pipelines for Sexual Dysfunctions Treatment 8.1 R&D Pipeline Drugs for Male Sexual Dysfunctions – Still Dominated by ED 8.1.1 Tissue Genesis Cell Isolation System (Tissue Genesis, Inc.) – ED 8.1.2 Adipose-Derived Stem Cell Injection (Ageless Regenerative Institute) – ED 8.1.3 Selegiline (University of South Florida) – ED 8.1.4 VL#FIA3-30 (VasoLead) – ED 8.1.5 MED2002 (Futura Medical) – ED 8.1.6 MED2005 (Futura Medical Developments Ltd) - ED 8.1.7 Fispemifene (NexMed) – ED and Secondary Hypogonadism 8.1.8 Transdermal Androgel (Johns Hopkins University) – Priapism 8.1.9 Adipose Tissue Stem Cell Injection (Man Clinic for Andrology, Male Infertility and Sexual Dysfunction) – Peyronie’s Disease 8.1.10 AA4500 and ErecAid Esteem Manual Vacuum Therapy System (Endo Pharmaceuticals) – Peyronie’s Disease 8.1.11 H-22411(Allergan) – Peyronie’s Disease 8.1.12 AA4500 (Allergan) - Peyronie’s Disease 8.1.13 IX-01 (Ixchelsis Limited) - Premature Ejaculation 8.1.14 CDFR0812-15 (CTC Bio, Inc.) – Premature Ejaculation 8.2 R&D Pipeline Drugs for Female Sexual Dysfunctions – Emerging Therapies 8.2.1 Tribulus Terrestris – Female Hypoactive Sexual Desire Disorder 8.2.2 Bremelanotide (Palatin Technologies) – Female Hypoactive Sexual Desire Disorder 8.2.3 Lybridos (Emotional Brain NY Inc.) – Female Hypoactive Sexual Desire Disorder 8.2.4 Lorexys (S1 Biopharma) - Female Hypoactive Sexual Desire Disorder 8.2.5 SST-6007 (Strategic Science & Technologies, LLC) - Female Hypoactive Sexual Desire Disorder 8.2.6 TBS-2 (Acerus Pharmaceuticals Corporation) – Orgasmic Disorder 8.2.7 SST-6006 (Strategic Science & Technologies, LLC) – Female Sexual Dysfunction 8.2.8 Fluocinonide Cream (OHSU Knight Cancer Institute National Cancer Institute (NCI)) – Painful Sexual Intercourse
9. Qualitative Analysis of the Sexual Dysfunctions Drugs Market 2015-2026 9.1 SWOT Analysis of the Sexual Dysfunctions Drugs Market, 2015-2026 9.1.1 Strengths 9.1.2 Weaknesses 9.1.3 Opportunities 9.1.4 Threats 9.2 STEP Analysis of the Sexual Dysfunctions Drugs Market, 2015-2026 9.2.1 Social 9.2.2 Technological 9.2.3 Economic 9.2.4 Political
10. Research Interviews from Our Survey – 2015 10.1 Dr. Carl Spana and Mr. Stephen Wills, Palatin Technologies 10.1.1 Palatin Technologies, Inc. 10.1.2 Female Sexual Dysfunction Market – What Are the Challenges? 10.1.3 Industry Effort to Bridge the Gaps 10.1.4 Drivers and Restraints of the FSD Market 10.1.5 Bremelanotide – On-Demand Treatment for HSDD 10.1.6 Designing Clinical Trials to Assess Drugs for FSDs – Remains a Challenge? 10.1.7 Commercial Potential of Bremelanotide 10.2 James Barder, CEO, Futura Medical 10.2.1 Futura Medical 10.2.2 Will the ED Treatment Market Show Growth? 10.2.3 Unmet Needs of ED Treatment and Management 10.2.4 MED2002 for ED - Targeted Delivery 10.2.5 DermaSys – Improves Permeation of APIs through the Skin 10.2.6 DermaSys –Therapeutic Benefits to Other Therapeutic Areas? 10.2.7 MED2002 – Could Potentially Meet the Unmet Demand in ED
11. Conclusions 11.1 Male Sexual Dysfunction Drugs Market 11.2 Female Sexual Dysfunction Drugs Market 11.3 Leading National Markets 11.4 Drugs in the Pipeline
List of Tables Table 1.1 Global Sexual Dysfunction Drugs Market: Regional and National Submarket Revenue Forecasts ($bn), 2015-2026 Table 3.1 Global Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 3.2 Global Sexual Dysfunction Drugs Market Revenue by Drug Class: Forecasts ($bn), 2015-2026 Table 3.3 Global PDE5 Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 3.4 Global Prostaglandins Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 3.5 Global Androgens Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 3.6 Global Gonadotrophins Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 3.7 Global Other Drug Classes Market: Grouped Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 3.8 Global Sexual Dysfunction Drugs Market by Drug Class: Submarket Shares (%), 2015-2026 Table 3.9 Global Sexual Dysfunction Drugs Market Revenue by Gender: Forecasts ($bn), 2015-2026 Table 3.10 Global Male Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 3.11 Global Female Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 3.12 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2015-2026 Table 4.1 Leading Sexual Dysfunction Drugs by Revenue ($bn), 2014 Table 4.2 Cialis Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 4.3 Viagra Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 4.4 Gonal-F Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 4.5 Puregon Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 4.6 Decapeptyl Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 4.7 Caverject Dual Chamber Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 4.8 Levitra Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 4.9 Nebido Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 4.10 Testim Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 4.11 Priligy Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 4.12 Stendra/Spedra Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 4.13 MUSE Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 4.14 Viridal Duo/Edex Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 4.15 Tostran Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 4.16 Leading Sexual Dysfunction Drugs, Market Shares (%), 2015-2026 Table 6.1 Top Companies for Sexual Dysfunction Drugs: Revenues ($bn) and Market Shares (%), 2014 Table 6.2 Eli Lilly– Revenue ($bn) and Share (%), 2014 Table 6.3 Pfizer– Revenue ($bn) and Share (%), 2014 Table 6.4 Merck KGaA– Revenue ($bn) and Share (%), 2014 Table 6.5 Merck & Co. – Revenue ($bn) and Share (%), 2014 Table 6.6 Ipsen Ltd – Revenue ($bn) and Share (%), 2014 Table 6.7 Bayer – Revenue ($bn) and Share (%), 2014 Table 7.1 Global Sexual Dysfunction Drugs Market: National Submarket Revenue Forecasts ($bn), 2015-2026 Table 7.2 Grouped Global Sexual Dysfunction Drugs Market: Regional Submarket Revenue Forecasts ($bn), 2015-2026 Table 7.3 US Sexual Dysfunction Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 7.4 Japanese Sexual Dysfunction Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 7.5 EU5 Sexual Dysfunction Drugs Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 7.6 BRIC Sexual Dysfunction Drugs Market: Revenue Forecasts ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 7.7 Other Regions’ Sexual Dysfunction Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 8.1 List of Selected Drug Candidates for Male Sexual Dysfunctions Table 8.2 List of Selected Drug Candidates for Female Sexual Dysfunctions Table 9.1 Strengths, Weaknesses, Opportunities and Threats in the Sexual Dysfunction Drugs Market, 2015 Table 9.2 Social, Technological, Economic and Political Analysis of the Sexual Dysfunction Drugs Market, 2015 Table 11.1 Global Sexual Dysfunction Revenue Forecasts ($bn), CAGR (%) and Market Share (%) by Product Category, 2014, 2020, 2026 Table 11.2 Global Sexual Dysfunction Revenue Forecasts ($bn), CAGR (%) and Market Shares (%) by Region, 2014, 2020, 2026
List of Figures Figure 3.1 The Global Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026 Figure 3.2 Global PDE5 Market: Revenue Forecast ($bn), 2015-2026 Figure 3.3 Global Prostaglandins Market: Revenue Forecast ($bn), 2015-2026 Figure 3.4 Global Androgens Market: Revenue Forecast ($bn), 2015-2026 Figure 3.5 Global Gonadotrophins Market: Revenue Forecast ($bn), 2015-2026 Figure 3.6 Global Other Drug Classes Market: Grouped Revenue Forecast ($bn), 2015-2026 Figure 3.7 Global Sexual Dysfunction Drugs Market by Drug Class: Revenue Forecasts ($bn), 2015-2026 Figure 3.8 Global Sexual Dysfunction Drugs Market by Drug Class: Submarket Share (%), 2015-2026 Figure 3.9 Global Male Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026 Figure 3.10 Global Female Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026 Figure 3.11 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2014 Figure 3.12 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2020 Figure 3.13 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2026 Figure 3.14 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2015-2026 Figure 3.15 Global Sexual Dysfunction Drugs Market: Submarket Forecasts ($bn), 2015-2026 Figure 4.1 Cialis Revenue Forecast ($bn), 2015-2026 Figure 4.2 Viagra Revenue Forecast ($bn), 2015-2026 Figure 4.3 Gonal-F Revenue Forecast ($bn), 2015-2026 Figure 4.4 Puregon Market Forecast ($bn), 2015-2026 Figure 4.5 Decapeptyl Market Forecast ($bn), 2015-2026 Figure 4.6 Caverject Dual Chamber Market Forecast ($bn), 2015-2026 Figure 4.7 Levitra Revenue Forecast ($bn), 2015-2026 Figure 4.8 Nebido Revenue Forecast ($bn), 2015-2026 Figure 4.9 Testim Revenue Forecast ($bn), 2015-2026 Figure 4.10 Priligy Revenue Forecast ($bn), 2015-2026 Figure 4.11 Stendra/Spedra Market Forecast ($bn), 2015-2026 Figure 4.12 MUSE Revenue Forecast ($bn), 2015-2026 Figure 4.13 Viridal Duo/Edex Revenue Forecast ($bn), 2015-2026 Figure 4.14 Tostran Revenue Forecast ($bn), 2015-2026 Figure 4.15 Leading Sexual Dysfunction Drugs, Market Shares (%), 2015-2026 Figure 6.1 Top Producers of Sexual Dysfunction Drugs: Market Shares (%), 2014 Figure 6.2 Eli Lilly’s Drugs by Share of Company Revenue (%), 2014 Figure 6.3 Pfizer’s Drugs by Share of Company Revenue (%), 2014 Figure 6.4 Merck KGaA’s Drugs by Share of Company Revenue (%), 2014 Figure 6.5 Merck & Co.’s Drugs by Share of Company Revenue (%), 2014 Figure 6.6 Ipsen Ltd.’s Drugs by Share of Company Revenue (%), 2014 Figure 6.7 Bayer’s Drugs by Share of Company Revenue (%), 2014 Figure 7.1 Global Sexual Dysfunction Drugs Market: Regional Submarket Revenue Forecasts ($bn), 2015-2026 Figure 7.2 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2014 Figure 7.3 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2020 Figure 7.4 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2026 Figure 7.5 Global Sexual Dysfunction Drugs Market: Submarket Shares (%), 2014-2026 Figure 7.6 US Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026 Figure 7.7 Japanese Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026 Figure 7.8 EU5 Sexual Dysfunction Drugs Market: Revenue Forecasts ($bn), 2015-2026 Figure 7.9 EU5 Sexual Dysfunction Drugs Market: Submarket Shares (%), 2014 Figure 7.10 EU5 Sexual Dysfunction Drugs Market: Submarket Shares (%), 2020 Figure 7.11 EU5 Sexual Dysfunction Drugs Market: Submarket Shares (%), 2026 Figure 7.12 EU5 Sexual Dysfunction Drugs Market: Submarket Shares (%), 2015-2026 Figure 7.13 BRIC Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026 Figure 7.14 BRIC Sexual Dysfunction Drugs Market: Submarket Shares (%), 2014 Figure 7.15 BRIC Sexual Dysfunction Drugs Market: Submarket Shares (%), 2020 Figure 7.16 BRIC Sexual Dysfunction Drugs Market: Submarket Shares (%), 2026 Figure 7.17 BRIC Sexual Dysfunction Drugs Market: Submarket Shares (%), 2015-2026 Figure 7.18 Other Regions’ Sexual Dysfunction Drugs Market: Revenue Forecast ($bn), 2015-2026
A. Menarini Pharma UK SRL Acerus Pharmaceuticals Corporation Actavis Ageless Regenerative Institute Allergan American Psychiatric Association Apotex Corp. Apotex Inc. Aspen Pharma Trading Auxilium Pharmaceuticals Bayer Besins Healthcare UK Cipla CTC Bio, Inc. Eli Lilly EMA Emotional Brain NY Inc. Endo Pharmaceuticals FDA Federal University of Minas Gerais Ferring Pharmaceuticals Finox Biotech UK & Ireland Futura Medical Glennwood, GmbH Hetero Labs Limited Ipsen Ltd. Ixchelsis Johns Hopkins University Johnson & Johnson Man Clinic for Andrology, Male Infertility and Sexual Dysfunction Meda Pharmaceuticals Merck & Co. Merck KGaA Mylan Pharmaceuticals NexMed OHSU Knight Cancer Institute Palatin Technologies Pfizer Pharmasure Procter & Gamble ProStrakan Pharmaceuticals S1 Biopharma Sprout Pharmaceuticals Strategic Science & Technologies LLC Swedish Orphan Biovitrum Ltd (SOBI) Takeda Tissue Genesis, Inc. UCB Unimed Pharmaceuticals University of South Florida Valeant Pharmaceuticals VasoLead VIVUS Watson Pharmaceuticals World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Male and Female Sexual Dysfunctions: Drug Market Report and Forecasts 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
